Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission

This study is currently recruiting participants.
Verified July 2012 by Asan Medical Center
Sponsor:
Information provided by (Responsible Party):
Kyoo-Hyung Lee, Asan Medical Center
ClinicalTrials.gov Identifier:
NCT01020734
First received: November 24, 2009
Last updated: July 23, 2012
Last verified: July 2012

November 24, 2009
July 23, 2012
May 2011
December 2013   (final data collection date for primary outcome measure)
Efficacy of the treatment measured in terms of frequency of relapse and duration of remission [ Time Frame: up to 2 years after transplantation ] [ Designated as safety issue: No ]
duration of CR, leukemia recurrence
Efficacy of the treatment measured in terms of frequency of relapse and duration of remission [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01020734 on ClinicalTrials.gov Archive Site
  • Engraftment [ Time Frame: up to 35 days after transplantation ] [ Designated as safety issue: Yes ]
    achievement of neutrophil count over 500/ul
  • Acute and chronic graft-versus-host disease [ Time Frame: up to 100 days for acute GVHD and up to 2 years for chronic GVHD ] [ Designated as safety issue: Yes ]
  • Treatment-related mortality [ Time Frame: up to 2 years after transplantation ] [ Designated as safety issue: Yes ]
  • Leukemia-free survival and overall survival [ Time Frame: up to 2 years after transplantation ] [ Designated as safety issue: No ]
  • Engraftment [ Designated as safety issue: No ]
  • Donor chimerism at 2 and 4 weeks after HSCT [ Designated as safety issue: No ]
  • Secondary graft failure [ Designated as safety issue: No ]
  • Acute and chronic graft-versus-host disease [ Designated as safety issue: Yes ]
  • Treatment-related mortality [ Designated as safety issue: No ]
  • Leukemia-free survival and overall survival [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Donor Stem Cell Transplant or Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia in Remission
Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Myelogenous Leukemia in Remission Using HLA-Matched Sibling Donors, HLA-Matched Unrelated Donors, or HLA-Mismatched Familial Donors - A Phase 2 Study

RATIONALE: Giving chemotherapy before a donor bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and methotrexate before and after transplant may stop this from happening.

PURPOSE: This phase II trial is studying how well donor stem cell transplant or bone marrow transplant works in treating patients with acute myeloid leukemia in remission.

OBJECTIVES:

Primary

  • Evaluate the efficacy of allogeneic hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation (BMT) from a HLA-matched sibling donor, HLA-matched unrelated donor, or HLA-mismatched familial donor, in terms of the frequency of relapse and duration of remission, in patients with acute myeloid leukemia (AML) who have either achieved complete remission (CR1) after induction chemotherapy or who experienced recurrent AML then achieved second CR (CR2) after salvage chemotherapy.

Secondary

  • Determine the engraftment, donor chimerism, and secondary graft failure in these patients.
  • Assess acute and chronic graft-vs-host disease, immune recovery, and infections in these patients.
  • Determine transplantation-related mortality, leukemia-free survival, and overall survival of these patients.

OUTLINE:

  • Conditioning chemotherapy and allogeneic bone marrow or hematopoietic stem cell transplantation (HSCT): After completion of induction chemotherapy and a resulting complete response (CR1) or salvage chemotherapy resulting in CR2, patients receive 1 of the following conditioning regimens and transplantations determined by age, co-morbidity, and type of available donor:

    • 15 to 55 years of age without significant co-morbidity* undergoing HLA-matched sibling bone marrow transplantation (BMT) (BuCy conditioning): Patients receive busulfan IV once daily on days -7 to -4 and cyclophosphamide IV over 1-2 hours once daily on days -3 and -2. Patients then undergo an allogeneic BMT on day 0.
    • Older than 55 years or younger than 55 years with co-morbidity* undergoing HLA-matched sibling BMT; patients of any age undergoing HLA-matched unrelated HSCT; and for patients of any age undergoing HLA-mismatched familial donor HSCT (BuFluATG conditioning): Patients receive busulfan IV once daily on days -7 and -6, fludarabine phosphate IV over 30 minutes once daily on days -7 to -2, anti-thymocyte globulin IV over 4 hours once daily on days -3 to -1, and methylprednisolone IV over 30 minutes once daily on days -4 to -1. Patients then undergo either an allogeneic BMT on day 0 or allogeneic peripheral blood hematopoietic stem cell infusions on days 0-1 or 0-2.

NOTE: *Significant co-morbidity is defined as residual fungal or other infections in the lung or other viscera and residual organ toxicities occurring during induction or consolidation chemotherapy.

  • GVHD prophylaxis: Patients receive cyclosporine orally or IV over 2-4 hours twice daily beginning on day -1 followed by a taper starting on day 30 (BuFluATG conditioning) or day 60 (BuCy conditioning). Patients also receive methotrexate IV on days 1, 3, and 6 after the last day of donor cell infusion.
  • CNS prophylaxis: Patients receive intrathecal (IT) methotrexate once before conditioning regimen. Patients receive IT methotrexate once every 2 weeks for 3 times after transplantation and platelet recovery. Patients also receive leucovorin calcium orally or IV over 4 hours after IT methotrexate and then once every 6 hours for a total of 8 doses after each dose of IT methotrexate.

After completion of study therapy, patients are followed every 3 months for 3 years and then annually.

Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
  • Biological: anti-thymocyte globulin
  • Drug: busulfan
  • Drug: cyclophosphamide
  • Drug: cyclosporine
  • Drug: fludarabine phosphate
  • Drug: methotrexate
  • Procedure: allogeneic hematopoietic stem cell transplantation
Experimental: transplantation
perform allogeneic HCT for patients with AML in CR1; then analyze various pre-transplantation variable, including donor type, for correlation to outcomes
Interventions:
  • Biological: anti-thymocyte globulin
  • Drug: busulfan
  • Drug: cyclophosphamide
  • Drug: cyclosporine
  • Drug: fludarabine phosphate
  • Drug: methotrexate
  • Procedure: allogeneic hematopoietic stem cell transplantation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
200
Not Provided
December 2013   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of acute myeloid leukemia (AML) meeting 1 of the following criteria:

    • Achieved complete response (CR1) after induction chemotherapy
    • Recurrent AML that went into second CR (CR2) after salvage chemotherapy, except those who have undergone prior allogeneic HSCT
  • No acute promyelocytic leukemia or acute myeloid leukemia with chromosomal changes t(8;21), inv 16, or t(15;17)
  • Must have a donor available meeting one of the following criteria:

    • HLA-matched sibling of 65 years or younger
    • 6/6 HLA-matched unrelated donor (younger than 55 years) for antigen A, B, and DR
    • HLA-mismatched family member (offspring, parents, haploidentical sibling)

PATIENT CHARACTERISTICS:

  • Karnofsky performance status 70-100%
  • Bilirubin < 2.0 mg/dL
  • AST < 3 times the upper limit of normal
  • Creatinine < 2.0 mg/dL
  • Ejection fraction > 40% on MUGA scan
  • Negative pregnancy test

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
15 Years to 75 Years
No
Not Provided
Korea, Republic of
 
NCT01020734
CDR0000659891, AMC-UUCM-2009-0579
No
Kyoo-Hyung Lee, Asan Medical Center
Asan Medical Center
Not Provided
Principal Investigator: Kyoo H. Lee, MD Asan Medical Center
Asan Medical Center
July 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP